What an exciting time to be treating cancer patients! The advances in treatment over the past few years now generate tremendous optimism that you can see on our patient’s faces.
Work and Credentials:
Primary Location
Other Location
Position
Medical Oncologist
Board Certification
Medical Oncology, Hematology and Internal Medicine
Fellowship
New York Hospital/Cornell University Medical College, Medical Oncology and Hematology
Internship
New York Hospital/Cornell University Medical College
Residency
New York Hospital/Cornell University Medical College
Medical School
Cornell University School of Medicine
College
Harvard College
Special Interests
Genitourinary cancers, leukemia/lymphoma, coagulation disorders
With a specific interest in teaching, Dr. Feigert has held several instructional positions throughout his career. After earning his Medical Degree from the Cornell University School of Medicine, he spent a year as an Instructor of Medicine at the Cornell University Medical College and another year as the Medical Director of the Division of Oncology at Elliot Hospital in Manchester, New Hampshire. Dr. Feigert has also served as a Clinical Assistant Professor at Georgetown University Medical Center and at the Virginia Commonwealth University’s INOVA Fairfax campus.
Dr. Feigert has been recognized as a Top Doctor in both Northern Virginia Magazine and Washingtonian magazine. He has also been recognized by the Alpha Omega Alpha Honor Medical Society. Dr. Feigert is a member of several professional organizations including the American Society of Clinical Oncology, the American Society of Hematology and the Arlington County Medical Society. He is actively involved in local tumor boards, and he supports international communities through his participation with the Virginia Hospital Center Medical Brigade, a volunteer organization that helps bring clean water and health care to areas in Honduras.
During his spare time, Dr. Feigert is an active tennis player.
Physician Video:
'
Physician Publications
October 1, 2015
Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.
Read MoreJune 10, 2012
Deferasirox Reduces Serum Ferritin and Labile Plasma Iron in RBC Transfusion-Dependent Patients with Myelodysplastic Syndrome.
Read MoreMore Publications by John Feigert, MD
March 1, 2010
Oncologists’ Experience in Reporting Cancer Staging and Guideline Adherence: Lessons From the 2006 Medicare Oncology Demonstration.
Read MoreNovember 1, 2009
Two-Year Analysis of Efficacy and Safety of Deferasirox (Exjade®) Treatment in Myelodysplastic Syndrome Patients Enrolled in the US03 Study.
Read MoreNovember 1, 2008
Iron Chelation with Deferasirox (Exjade®) Improves Iron Burden in Patients with Myelodysplastic Syndromes (MDS)
Read MoreNovember 16, 2007
Deferasirox (ICL670; Exjade) Reduces Serum Ferritin and Labile Plasma Iron in Patients with Myelodsyplastic Syndromes.
Read MoreJanuary 1, 1998
A Comparison of Efficacy of Sargramostim (yeast-derived Rhu GM-CSF) and Filgrastim (Bacteria-derived Rhu G-CSF) in the Therapeutic Setting of Chemotherapy-induced Myelosuppression.
Read MoreJuly 1, 1997
Randomized Trial Comparing the Tolerability of Sargramostim (yeast-derived RhuGM-CSF) and Filgrastrim (Bacteria-derived RhuG-CSF) in Cancer Patients Receiving Myelosuppressive Chemotherapy.
Read MoreSeptember 1, 1996
Rapidly Progressive Prostate Cancer in the Primary Care Setting.
Read MoreJanuary 1, 1990
Multicentric Angiofollicular Lymph Node Hyperplasia with Peripheral Neuropathy, Pseudotumor Cerebri, IgA Dysproteinemia, and Thrombocytosis in Women: A Distinct Clinicopathology Entity.
Read MoreJanuary 1, 1988
Tissue Plasminogen Activator Binds to Immobilized Immunoglobulin G: Enhancement by Plasmin and the Identification of Plasmin Derived Fab as the t-PA Binding Fragment.
Read MoreJanuary 30, 1987
Porcine Factor VIII Controls Severe Bleeding in Acquired Von Willebrand's Disease By Supplying Von Willebrand's Factor.
Read More
